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Abstract
BACKGROUND—The overall age-standardized cancer incidence rate continues to decline 
whereas the number of cases diagnosed each year increases. Predicting cancer incidence can help 
to anticipate future resource needs, evaluate primary prevention strategies, and inform research.
METHODS—Surveillance, Epidemiology, and End Results data were used to estimate the 
number of cancers (all sites) resulting from changes in population risk, age, and size. The authors 
projected to 2020 nationwide age-standardized incidence rates and cases (including the top 23 
cancers).
RESULTS—Since 1975, incident cases increased among white individuals, primarily caused by 
an aging white population, and among black individuals, primarily caused by an increasing black 
population. Between 2010 and 2020, it is expected that overall incidence rates (proxy for risk) will 
decrease slightly among black men and stabilize in other groups. By 2020, the authors predict 
annual cancer cases (all races, all sites) to increase among men by 24.1% (−3.2% risk and 27.3% 
age/growth) to >1 million cases, and by 20.6% among women (1.2% risk and 19.4% age/growth) 
to >900,000 cases. The largest increases are expected for melanoma (white individuals); cancers 
of the prostate, kidney, liver, and urinary bladder in males; and the lung, breast, uterus, and 
thyroid in females.
CONCLUSIONS—Overall, the authors predict cancer incidence rates/risk to stabilize for the 
majority of the population; however, they expect the number of cancer cases to increase by >20%. 
A greater emphasis on primary prevention and early detection is needed to counter the effect of an 
aging and growing population on the burden of cancer.
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INTRODUCTION
Each year, the “Annual Report to the Nation on the Status of Cancer” documents a sustained 
decline in the overall age-standardized cancer incidence rate beginning in the early 1990s, 
largely because of a decrease in the incidence of lung and prostate cancer in men and a 
decrease in colorectal cancer incidence in both sexes.1 This is a positive development 
because the age-standardized incidence rate approximates the population’s risk of being 
diagnosed with cancer and is useful for comparing the cancer burden between populations or 
over time within a population. The declining overall incidence rate means that for the 
majority of the population, the overall risk of being diagnosed with cancer has declined. 
However, these rates do not convey the full extent of the cancer burden, because they have 
the effect of removing the influence of demographic changes in the population.
The number of new cancer cases diagnosed each year is a function of the population’s risk 
of being diagnosed with cancer and the population’s age structure and size. Although the 
incidence rate has declined, the actual number of cases diagnosed each year has increased.2 
This increase reflects the finding that the risk of being diagnosed with cancer generally 
increases with age,3 and over the past several decades, the US population has grown, 
particularly in the older age groups.4 These demographic changes and increasing cancer 
burden are forecast to continue into this century as the cohort born after World War II, with 
increased longevity compared with earlier generations, enters the age groups most at risk of 
a cancer diagnosis.4-6 Less attention is given to the potential impact that the growing 
number of incident cases will have on the cancer surveillance and control community and on 
the health care system in the United States.
Trends in population risk, size, and age structure have been used to predict cancer incidence 
in several countries, including Canada,7 England,8,9 and the Nordic countries,10 and for 
world regions.11 In the current study, we used data from the National Cancer Institute’s 
Surveillance, Epidemiology, and End Results (SEER) program12 to assess the impact of 
changes in population risk, age structure, and growth on the cancer burden between 1975 
and 2009, and to project age-standardized cancer incidence rates and case counts (all sites 
and the top 23 cancers) according to these changes by sex and race for the entire US 
population from 2010 to 2020. The year 2020 was selected to align with Healthy People 
2020 (healthypeople.gov/2020/topicsobjectives2020/), which includes national goals and 
objectives in 42 topic areas, including cancer mortality. Herein, we discuss how these data 
can provide information to anticipate resource requirements to screen, diagnose, treat, and 
care for patients with cancer. Predictions of site-specific cancers can also help cancer control 
planners evaluate the effectiveness of prevention strategies13,14 and alert researchers to early 
changes in population risk.
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We obtained data for patients diagnosed from 1975 through 2009 covering approximately 
10% of the US population (SEER 9 registry [SEER 9]) from the SEER program.15 All 
invasive cancers were selected and grouped according to the top 23 cancers among men and 
women using the SEER site groups.3 Population estimates produced by the US Census 
Bureau were obtained from the SEER program.3 Population projections of the resident 
population by age, sex, and race from 2010 through 2020 were obtained from the US Census 
Bureau’s Population Projections program.16
Analytic Methods
Past cancer incidence: 1975 through 2009—To estimate the relative contribution to 
changes in the number of cancer cases diagnosed each year (1976-2009) attributed to 
changes in population risk, size, and age structure, we generated 3 sets of case counts by sex 
and race (white and black) based on a method first published in the 1999 Canadian Cancer 
Statistics report.17 The baseline for this analysis was the number of cases diagnosed in 1975.
Predicting cancer incidence: 2010 through 2020—To predict cancer incidence from 
2010 through 2020, we used Nordpred software,18 which is available from the Cancer 
Registry of Norway Web site (kreftregisteret.no/software/nordpred). The program used an 
age-period-cohort (APC) regression model with input data aggregated into six 5-year 
calendar periods (1980-2009) and 15 age groups (15-19 years, 20-24 years …80-84 years, 
and ≥ 85 years). Separate models were fit for each cancer site by sex and race (all, black, 
and white): Rap = (Aa + D•p + Pp + Cc)5 in which the dependent variable Rap is the 
incidence rate in age group a in calendar period p. Aa is the age component for age group a, 
D is the drift parameter (the common linear effect of both calendar period and birth cohort), 
Pp is the nonlinear period component of period p, and Cc is the nonlinear cohort component 
of cohort. We synthetically created cohorts by subtracting the age group midpoint from the 
period group midpoint. To offset exponential increases or decreases in incidence rates, we 
used the Power-5 link function. Assuming that trends are not likely to continue indefinitely, 
the drift component D was reduced by 25% and 50%, respectively, in the second and third 
calendar periods. Both of these modifications have been shown empirically to improve 
predictions.18 A chi-square goodness-of-fit test was used to choose the number of calendar 
periods (4-6 candidate periods) to include in the model. We based predictions on long-term 
trend data unless there was statistically significant curvature (P <.05) in the trend over time, 
in which case the linear drift component was based on the most recent 10-year period. 
Visual inspection was used to determine the starting age for each cancer site, sex, and race 
group such that each age group contained ≥10 cases. We age-standardized incidence rates 
per 100,000 using the US 2000 standard population weights.19
For cancer of the female breast and prostate, we used a modified approach to account for 
2003 breast cancer incidence decreases attributed to a reduction in the use of hormone 
replacement therapy20,21 and fluctuations in prostate cancer incidence related to the use of 
the prostate-specific antigen test.22 We based predictions for these cancers on data from 
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2005 through 2009. This is a reasonable assumption for breast cancers, because recent 
incidence rates are no longer declining,1,23 but might overestimate prostate cancers because 
recent rates continue to decline,1 particularly in older age groups.24 We based predictions 
for all sites combined on summed estimates among the cancer sites categories, including 
other cancer sites combined.
We obtained predicted cancer incidence counts for the entire US population by multiplying 
the age-specific rates to the 2010 through 2020 population projections. We apportioned 
cancer cases into the contribution from the change in population risk and changes in 
population size and age structure combined (denoted as the demographic component) 
according to methods described by Moller et al,10 using 2020 as the baseline.
RESULTS
Figure 1 and Table 1 show the contribution to the changes in the total number of cases by 
diagnosis year that we can attribute to changes in population risk, size, and age by sex and 
race. Between 1975 and 2009, the number of cases diagnosed increased by 95.3% among 
white males, 76.6% among white females, 183.4% among black males, and 192.9% among 
black females. Among white men, 17.3% of the increase (16.5%/95.3%) was because of a 
change in risk, 33.2% (31.6%/95.3%) was because of population growth, and 49.5% (47.2%/
95.3%) was because of an aging population. Among white females, 21.1% of the increase 
was because of a change in risk, 34.2% was because of growth, and 44.7% was because of 
aging. Among black males, 13.0% of the increase was because of a change in risk, 62.5% 
was because of growth, and 24.4% was because of aging. Among black females, 8.3% of the 
increase was because of a change in risk, 56.3% was because of growth, and 35.4% was 
because of aging.
Table 2 shows the predicted cases for 2010 and 2020 for the entire US population by sex and 
race, with the total percentage difference in the cases apportioned to the change due to risk 
and demographics. A percentage change of ≥5% was noted as an increase or decrease; 
otherwise cases were considered stable. Between 2010 and 2020, total cases are predicted to 
increase by 24.1% (−3.2% risk and 27.3% demographics) to >1 million annual cases in men, 
and by 20.6% (1.2% risk and 19.4% demographics) to >900,000 annual cases in women. 
Risk is predicted to stabilize for white individuals of both sexes and black women, and 
decline (7.9%) in black men. Results varied by cancer site. Figure 2 shows age-adjusted 
incidence rates from 1975 through 2009 (observed) and from 2010 through 2020 (predicted) 
for all sites combined and the top 10 cancers in men and women, with the largest predicted 
increase in incident cases between 2010 and 2020. Note that the scale on the y-axis varies 
according to cancer site.
Figure 3 shows the rank order of cases predicted to be diagnosed in 2010 by sex, for all 
races combined. The number of cases predicted to have been diagnosed in 2010 is shown in 
dark shading and the addition of cases predicted to be diagnosed in 2020 is shown in light 
shading. The largest increases in incident cases are expected in melanoma (among white 
individuals) and cancers of the prostate, kidney, liver, and urinary bladder in males and of 
the lung, breast, uterus, and thyroid in females.
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Over the next decade, we predict cancer incidence rates/risk to stabilize for much of the 
population. However, we expect the number of cancer cases to increase by >20% because of 
demographic changes in the US population. An increase in the number of incident cases of 
cancer has implications for the cancer surveillance and control community and for the health 
care system. A greater emphasis on primary prevention and early detection is needed to 
counter the effect of an aging and growing population on the burden of cancer.
Between 1975 and 2009, incident cases increased among white individuals, due primarily to 
an aging white population, and among black individuals, primarily because of a growing 
black population. Of particular note was the observation that population aging had little 
influence on cancer incidence in black men until the beginning of the 21st century. This is 
explained by the finding that compared with white individuals, life expectancy among black 
individuals in general, and black men in particular, was lower because of higher death rates 
from heart disease, cancer, homicide, diabetes, and perinatal conditions.25 Compared with 
white individuals, a higher percentage of black individuals spend more of their lives 
uninsured and in a state of poorer health.26 Racial disparities in life expectancy appear to be 
increasing in the US whereas overall life expectancy is increasing.27
The demographic components underlying the increasing cancer burden are likely to continue 
as the US population is expected to increase, with the largest increases expected in minority 
populations and in individuals aged >65 years.4 Between 2010 and 2020, the overall US 
population is expected to increase by 10%, with the percentage of those aged ≥65 years 
increasing from 13% to 16%. Changes in population risk (approxi-mated by the age-
standardized incidence rate) can exacerbate or attenuate the impact of these demographic 
trends.
Predicting future incident cases helps health planners and policy makers anticipate the 
resources needed to screen, diagnose, and treat patients newly diagnosed with cancer while 
providing ongoing care to cancer survivors. According to the results of the current study, 
between 2010 and 2020, total incident cases are predicted to increase by >20% to 
approximately 1.9 million cases diagnosed each year. During this time period, the overall 
cancer risk is predicted to stabilize in white individuals and black women and decline 
slightly among black men. Thus, the increase will be due primarily to demographic changes 
in the population. The largest increases will occur in prostate cancers in men and breast 
cancers in women.
In addition to an increase in the number of incident cases, there will be an accompanying 
increase in the number of cancer survivors, as patients with cancer overall are living longer 
after their diagnosis.3 In 2007, the number of cancer survivors was estimated to be 11.7 
million.28 It is projected to increase to 18 million by 2020.29 These increases have profound 
implications for the health care system in the United States. Over the past 2 decades, the 
financial cost of treating the most common cancers has nearly doubled,29,30 and these costs 
are expected to continue to increase.29,31 A projected shortage of oncologists is anticipated 
to strain the ability of the health care system to provide quality cancer care.32 In addition, 
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the increasing number of cases is expected to impact cancer registries as the workforce and 
resources required to register and follow patients with cancer will also increase.33
Cancer predictions also can help the cancer control community to target and evaluate 
prevention strategies by forecasting the cancer burden under various exposures to etiologic 
factors (eg, diet, physical activity, and tobacco use), screening and diagnostic procedures, 
and health care interventions.13,14 Apportioning the changing cancer burden into risk and 
demographic components helps put into perspective the effectiveness of these prevention 
strategies. Tobacco control efforts are a good example. Tobacco use, particularly cigarette 
smoking, is associated with several cancers, including those of the respiratory system (lung 
and bronchus), urogenital system (kidney and renal pelvis, urinary bladder, and cervix uteri), 
digestive system (colorectum, esophagus [squamous cell], liver, pancreas, and stomach), and 
head and neck (oral cavity, pharynx, and larynx).34 The connection between tobacco use and 
cancer risk is strongest for lung cancer. In the United States, cigarette use has declined since 
the release of the first US Surgeon General’s report on smoking and health in 1964.34 
Accounting for the long latency period between exposure and disease occurrence, incidence 
rates for lung cancer have decreased since the mid-1980s among men and the late 1990s 
among women, in parallel with decreases in tobacco use.35 The incidence of lung cancer has 
declined more rapidly among men than women.1,35
As shown in Figure 2, these trends are expected to continue as sex-specific and race-specific 
rates begin to converge.36 According to the results of the current study, the accelerated 
reduction in risk among men is expected to nearly offset the increase in the number of new 
incident cases expected in 2020 due to demographic changes. As a result, the number of new 
lung cancer cases in men is expected to stabilize between 2010 and 2020. However, lung 
cancer risk reductions in women will only partially offset the increase in the number of 
incident cases due to demographic changes and, as a result, >10,000 additional new lung 
cancer cases are expected to be diagnosed annually in women by 2020. Other tobacco-
related cancers demonstrate similar patterns of risk and case count reduction.
Cancer predictions can also alert researchers to the impact of changes in population risk 
before the full extent of the cancer burden manifests and thus suggest the need for new and 
enhanced prevention strategies or areas of etiologic research. The current study identified 
several cancers for which increasing risk is exacerbating demographic trends. Consider the 
obesity epidemic. Excess weight is associated with an increased risk of cancers of the female 
breast, colon and rectum, esophagus (adenocarcinomas), corpus uteri, pancreas, and kidney 
and renal pelvis.37 The rate of overweight and obesity has increased over the past several 
decades, and approximately two-thirds of adults and one-third of children currently are 
considered over-weight or obese.37 With the exception of breast and colorectal cancers, case 
counts for weight-related cancers are predicted to increase between 30% and 40% between 
2010 and 2020. Risk is also increasing for cancers with an infectious etiology. Cases of liver 
cancer are predicted to increase by >50%, most likely as the result of the epidemic increase 
in hepatitis infections, particularly among cohorts born between 1945 through 1965,38 and 
by approximately 30% for oral cancers in white men, likely the result of an increase in 
human papillomavirus infections.39 Thyroid and melanoma cancers have increased over the 
past several decades,40-43 and are predicted to continue to increase between 50% and 60%. 
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Although the reasons for these increases are not completely understood, they may relate in 
part to improved surveillance and access to care.
Strengths and Limitations
APC models identify trends in younger birth cohorts and extrapolate these trends to future 
older cohorts.10 These models have been validated in studies using long-term cancer 
incidence data.18 Although based on the best available information, predictions should be 
viewed with caution. For example, colorectal cancer was the site that most frequently 
demonstrated a poor fit using APC models for 5 of the 6 combinations of sex and race. APC 
models might not adequately reflect period effects related to screening.44,45 Other possible 
limitations include the following. First, the SEER 9 data, which cover only10% of the US 
population, are not representative of the entire US population. SEER 9 areas tend to be more 
urban and to have more foreign-born individuals compared with other parts of the United 
States.46 Recent data from the Centers for Disease Control and Prevention’s National 
Program of Cancer Registries (NPCR) covers 96% of the US population,2 but is only 
available from 1999 onward. In a comparison of SEER and NPCR data, incidence rates of 
colorectal cancer and tobacco-related cancers were higher in the NPCR, whereas rates of 
screen-detected cancers and cancers diagnosed in physician offices (such as breast cancer, 
prostate cancer, and melanoma) were higher in SEER.47 As such, the magnitude of the 
increase in case counts for certain cancers might be impacted by using SEER 9 data. For 
example, melanoma cases were lower in the predictions for all races combined compared 
with the predictions for white individuals for males and females.
This is because the percentage of white males and females was lower overall in the SEER 9 
areas compared with the US population. When NPCR data become available for a sufficient 
period of time, SEER and NPCR data combined should be used to predict future cancer 
incidence rates and counts. Second, population projections are themselves forecasts based on 
assumptions regarding future births, deaths, and migration and can therefore impact 
projections of incident counts and rates. Third, the change in the number of cases between 
time periods has been divided into changes due to risk, age structure, and population size. 
The decomposition is arbitrary because the 3 components mutually affect each other. For 
example, if the population size increases, the effect of higher incidence rates (risk) will be 
larger than if the population size does not change. In the analysis of past time trends, the 
base year (1975) was used as the reference year, following the Canadian approach.17 For 
future trends, we used the final year (2020) as the reference year following the method 
described in Moller et al.10 The consequence of using the final year as a reference rate is that 
the change in the number of cases because of the combined effect of risk, age structure, and 
population size is attributed to risk, not demographics. For future trends, we preferred this 
approach from a preventive prospective: if a future increase in risk can be prevented to 
maintain risk at the current level, the number of cases from the combined effect of risk and 
demographics can be avoided.
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(a-d) Trends in incident cases for all cancers and ages combined attributed to population risk 
and diagnostic practices, growth, and aging are shown. Surveillance, Epidemiology, and End 
Results SEER 9 registry data (1975-2009) are shown by sex and race (white vs black) in (a) 
white males, (b) white females, (c) black males, and (d) black females.
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(a-m) Trends in observed (solid line) and predicted (dotted line) age-standardized incidence 
rates are shown for all sites combined and the top 10 cancers in men and women with the 
largest predicted increase in incident cases (white and black individuals), 1975 through 
2020. NOS indicates not otherwise specified; IBD, inflammatory bowel disease.
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(a and b) Cancer site-specific incident cases predicted to be diagnosed in 2010 (dark 
shading) and additional cases predicted to be diagnosed in 2020 (lighter shading) are shown 
ranked by 2010 case counts by sex. CNS indicates central nervous system; IBD, 
inflammatory bowel disease.
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